OBJECTIVES: To identify all of the patients affected by chronic hepatitis C infection treated with TNF-α blockers (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab) in order to evaluate the safety profile. METHODS: A systematic review of the literature from January 1990 to October 2010. RESULTS: In total, 37 publications with data on 153 patients who were treated with anti-TNF-α agents in the setting of HCV infection were found. The mean anti-TNF-α treatment duration was 11.9 months. Ninety-one patients had RA, 22 had psoriasis, 6 had Crohn's disease and 14 patients had other chronic inflammatory diseases. To date, etanercept is the biological agent that has been most extensively used in the patients with HCV infection, with only one definitely confirmed case of HCV hepatitis worsening and five suspected cases (elevation of transaminases not associated with an increase in the HCV viral load and vice versa) in 110 treated patients. Treatment with this agent resulted in stable levels of liver transaminases and a stable viral load in 74 patients, with an improvement in HCV chronic liver disease in combination with IFN-ribavirin therapy in 29 patients. CONCLUSIONS: The safety profile of anti-TNF-α agents in the setting of HCV infection seems to be acceptable, even if differences in the hepatotoxic profile are apparent between different agents. In the absence of long-term and large, controlled clinical trials a definitive statement on the safety of anti-TNF-α therapies in the setting of chronic HCV infection cannot be made.
OBJECTIVES: To identify all of the patients affected by chronic hepatitis C infection treated with TNF-α blockers (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab) in order to evaluate the safety profile. METHODS: A systematic review of the literature from January 1990 to October 2010. RESULTS: In total, 37 publications with data on 153 patients who were treated with anti-TNF-α agents in the setting of HCV infection were found. The mean anti-TNF-α treatment duration was 11.9 months. Ninety-one patients had RA, 22 had psoriasis, 6 had Crohn's disease and 14 patients had other chronic inflammatory diseases. To date, etanercept is the biological agent that has been most extensively used in the patients with HCV infection, with only one definitely confirmed case of HCV hepatitis worsening and five suspected cases (elevation of transaminases not associated with an increase in the HCV viral load and vice versa) in 110 treated patients. Treatment with this agent resulted in stable levels of liver transaminases and a stable viral load in 74 patients, with an improvement in HCV chronic liver disease in combination with IFN-ribavirin therapy in 29 patients. CONCLUSIONS: The safety profile of anti-TNF-α agents in the setting of HCV infection seems to be acceptable, even if differences in the hepatotoxic profile are apparent between different agents. In the absence of long-term and large, controlled clinical trials a definitive statement on the safety of anti-TNF-α therapies in the setting of chronic HCV infection cannot be made.
Authors: Curtis Cooper; Stephan Shafran; Susan Greenbloom; Robert Enns; John Farley; Nir Hilzenrat; Kurt Williams; Magdy Elkashab; Nabil Abadir; Manuela Neuman Journal: Can J Gastroenterol Hepatol Date: 2013-11-08
Authors: Marc Beyer; Zeinab Abdullah; Jens M Chemnitz; Daniela Maisel; Jil Sander; Clara Lehmann; Yasser Thabet; Prashant V Shinde; Lisa Schmidleithner; Maren Köhne; Jonel Trebicka; Robert Schierwagen; Andrea Hofmann; Alexey Popov; Karl S Lang; Annette Oxenius; Thorsten Buch; Christian Kurts; Mathias Heikenwalder; Gerd Fätkenheuer; Philipp A Lang; Pia Hartmann; Percy A Knolle; Joachim L Schultze Journal: Nat Immunol Date: 2016-03-07 Impact factor: 25.606